Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 6.11.2019 | EN | Official Journal of the European Union | C 375/28 |

---

Prior notification of a concentration

(Case M.9331 — Danaher/GE Healthcare Life Sciences Biopharma)

(Text with EEA relevance)

(2019/C 375/08)

1.

On 29 October 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2019375EN.01002801-E0001).

This notification concerns the following undertakings:

|  |  |
| --- | --- |
| — | Danaher Corporation (‘Danaher’, USA), |

|  |  |
| --- | --- |
| — | GE Healthcare Life Sciences Biopharma Business (‘GE Biopharma’, USA), controlled by General Electric Company. |

Danaher acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of GE Biopharma.

The concentration is accomplished by way of purchase of shares and assets.

2.

The business activities of the undertakings concerned are:

|  |  |
| --- | --- |
| — | for Danaher: manufacturing and marketing professional, medical, industrial and commercial products and services, |

|  |  |
| --- | --- |
| — | for GE Biopharma: supplying instruments, consumables and software for the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs, such as monoclonal antibodies, vaccines, and cell and gene therapies. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9331 — Danaher/GE Healthcare Life Sciences Biopharma

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

|  |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

---

[Top](#document1)